Audrey’s Updated Selected Meeting Picks for May 2009.******************************************************************FountainBlue Life Science Entrepreneurs' Forum, Monday Evening, May 18, 2009

Topic: “How Regulatory and Reimbursement Changes Impact Today's Life Science Businesses”Date and time: Monday, May 18 from 5:30 p.m. - 7:30 p.m.Location: Wilson Sonsini, 950 Page Mill, Terrace 2 C & D, Palo AltoCost:         $20 members, $25 partners, $30 general         $40 for membership and event admissionRegistration:     http://www.acteva.com/booking.cfm?bevaid=162525 by May 15 atnoon, no exceptions please. Late and on-site registration is $40 - does notinclude membership.Audience:     Entrepreneurs, intrapreneurs and investors, no serviceproviders please

Topic Description

Success in today's life science regulatory environment requires balancingthe management and impact of federal, state and local policies on the rapidpace of technology development and science advancement in today's lifescience businesses. This month's seasoned life science specialists willshare their perspectives on the impact and interplay of regulatoryrequirements on reimbursement, technology development, science explorationand other business functions for life science entrepreneurs, intrapreneursand investors.***********************************************************************ACRP East Bay, Monday Evening, May 18th, 2009

Topic: Protocol Noncompliance: Deviations, Violations, and Beyond! Speaker: Maria Shabe, BSDate and Time:Monday, May 18th, 5:30 - 8:30 pm, 5:30 – 6:30 PM Registration, Networking, & Dinner Buffet6:30 – 7:00 PM  Welcome & Announcements7:00 – 8:30 PM  Educational ProgramLocation: UC Berkeley Extension - Room 202-204, 1995 University Ave, Berkeley, CA 94704 REGISTER NOW before May 13th Register early to assure admission; at the event IF space available (+$5 nonmembers). Contact hours NOT available at event. NCC ACRP member no Contact Hours: FreeNCC ACRP member WITH Contact Hours: $10ACRP member no Contact Hours: $10

1 5/13/2023

ACRP member WITH Contact Hours: $20Non - member no Contact Hours : $15Non - member WITH Contact Hours: $40

Topic DescriptionClinical protocol noncompliance can compromise data quality and human subject rights, safety, and welfare.  It can lead to clinical trial delays, regulatory authority rejection of the data, sanctions against those responsible for trial conduct and oversight, breaches of subject safety or rights, increased costs, or lack of public confidence in clinical trials or products.  Our guest speaker will present the perspective of local and international regulatory authorities on this issue. She will provide case studies of recent FDA warning letters and lead a review of the MHRA Guidance on serious breaches of GCP or the trial protocol. Strategies for preventative and corrective actions by sponsors and investigator sites will also be discussed. Educational ObjectivesAt the conclusion of this session, attendees should be able to: Define protocol deviations. Describe the perspective of local and international regulatory agencies on protocol compliance. Identify strategies for sponsors and investigator sites to improve protocol compliance.

Speaker Bio Maria has twenty eight years experience in the pharmaceutical, biologics, medical device and CRO industries. Maria held positions in data management/programming, clinical research, sales and marketing and over ten years in international clinical quality assurance. She established clinical quality units (GCP) for three pharma/biotech firms and one CRO.  Maria co-founded the Bay Area Clinical/Regulatory Roundtable (BACRR) in 1998.  The organization serves as an informational resource for Bay Area Clinical and Regulatory Professionals through presentations, group discussions, mentoring and exchange of ideas and experiences. She is also a member of the Society of Quality Assurance Professionals. ***************************************************************************Bio2Device Group, Tuesday Morning, May 19, 2009

Topic: “The power of E: Using eLearning to educate the highly educated” Speaker: Alycia Shilton-Lloyd, Ph.D., Chief Scientific Officer, GeneEd Inc.Date and Time: Tuesday, May 19, 2009, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: FreeParking on street and in NOVA and library parking lots across the street

Topic DescriptionThis presentation will cover how eLearning has (and can be) used by life sciences organizations to educate specialized work force teams on high-level content.  Examples of

2 5/13/2023

specialized teams will include: Physicians (Continuing Medical Education programs), biomanufacturing and QA personnel, Medical Science Liaisons, Clinical Trial Associates, implementation engineers, and R&D personnel.  Key steps in developing successful eLearning programs will also be discussed.

Speaker BioDr. Shilton-Lloyd received a doctorate in molecular, cellular, and developmental biology, a master of arts in philosophy, and a master of science in biology from Yale University. Her research involved the identification of a novel interaction between hormone response and cell adhesion. An experienced lecturer at the university undergraduate level, she designed and taught an advanced genetics course for a Yale-sponsored inner-city high school honors program. ******************************************************************PricewaterhouseCoopers/National Venture Capital Association, Tuesday Morning, May 19, 2009

Topic: “PWC’s Shaking the Money Tree”Moderator: Steve Bengston, PricewaterhouseCoopersPanelists:Stephen Bernardez, ONSET VenturesRich Brenner, The Brenner GroupTed Driscoll, Claremont Creek VenturesMatt Hemington, Cooley Godward Kronish LLPPrashant Shah, Hummer WinbladSanthosh Vadivelu, CanaanDate and Time: Tuesday morning, May 19, 2009. 7:30 am       Registration & Breakfast8:00 am - 10:00 am      Presentation and Panel DiscussionLocation: Cooley Godward Kronish LLP , 3175 Hanover Street, Palo Alto, CA 94304Fees:Pre-Registration: $30.00At the Door: $40.00

Topic DescriptionPlease join PricewaterhouseCoopers, Cooley Godward Kronish LLP and a distinguished panel as they provide insight into Q1 2009 Venture Investments, including PwC's Shaking the MoneyTree Report. The MoneyTreeTM Report is based on data from Thomson Reuters.

For information regarding registration, refund, course content, complaints, etc., please contact Melanie Rappa at (408) 817-7962 or melanie.rappa@us.pwc.com.***************************************************************************

BioScience Forum, Wednesday Evening, May 20, 2009

Topic: “Developing a Novel Drug for Alzheimer’s Disease: Unique Challenges and Opportunities”

3 5/13/2023

Speaker:  Lynn Seely, M.D., Chief Medical Officer, MedivationDate and Time: Wednesday, May 20, 2009; 6:00pm - 9:00pm6:00 PM - networking 7:00 PM - dinner 8:00 PM - presentationLocation: The Clarion Hotel, 401 East Millbrae Avenue, MillbraeFull info and Registration at:http://biosf.org/

Typical Cost: $50 before 11PM, Monday, May 18$60 on-site$30 full-time students pre-registration$35 full-time students on-site Acteva fees are added to the above prices Check website for latest information

Topic DescriptionThis presentation will focus on the unique challenges and opportunities of developing a drug for Alzheimer's disease, with the history of Medivation woven in. The talk will cover the mechanism of action of Medivation's novel drug, Dimebon, an overview of clinical data with Dimebon to date, as well as a discussion of the Dimebon clinical development program and partnership with Pfizer.

Speaker Biography:Dr. Seely joined Medivation as chief medical officer in May 2005. Medivation is currently in Phase 3 development of a novel drug for Alzheimer’s disease and Huntington’s disease. The program is partnered with Pfizer, Inc. In addition, Medivation is entering Phase 3 development for a novel androgen-receptor antagonist in patients with castration-resistant prostate cancer. From 2002 to 2005, Dr. Seely served as vice president of clinical development at Corgentech, Inc., a biomedical company. She served as vice president of clinical development at ProDuct Health, Inc., a privately-held medical device company, from 2000 to 2001, and subsequently served as vice president of clinical development for Cytyc Health Corporation, a medical device company and subsidiary of Cytyc Corporation, from 2001 to 2002. While there she assisted with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. From 1996 through 2000, she served as an associate director of clinical development at Chiron Corporation. Dr. Seely has led teams running clinical trials in all phases of development in a variety of therapeutic indications. Dr. Seely received an M.D. Alpha Omega Alpha from the University of Oklahoma, College of Medicine and completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital. She is board-certified in internal medicine and endocrinology and metabolism and was on faculty at the University of California, San Diego prior to joining industry.

***************************************************************************

IEEE, Engineering in Medicine and Biology Society (EMBS), Wednesday, May 20, 2009

Date and Time: Wednesday, May 20, 2009, 7:30 pm New Location:: Room M-114, Stanford University Medical School 

4 5/13/2023

Optional dinner, new location: Nexus Cafeteria in the Clark Center, 6:15 pm (no host, no reservations)Topic: “Targeting tumors with autonomous eyes: How the CyberKnife utilizes robotics and image guidance to annihilate cancer”Speaker: Michael Saracen

Topic DescriptionRobots are commonplace in many industries today demonstrating the benefits reliability, precision and accuracy have to offer. Medicine is entering a new age where it is starting to embrace technology, realizing some tasks are performed better and in some cases better performed by a machine. One area which has greatly benefited from this marriage of technology and medicine is Radiation Oncology. Targeting tumors inside the body with high precision and accuracy throughout a treatment is challenging, often requiring immobilization devices to prevent the patient from moving. The problem becomes significantly more difficult when treating tumors that move with respiration like those found in the lung, liver or pancreas. One system has successfully integrated robotics into patient setup and delivery of radiation, making treatments safer and more precise. Leveraging fully integrated image guidance capabilities, the system automatically adapts to movements and changes in the patient’s breathing patterns without user input. Robotics has a place in medicine, the question is, does it improve patient care and can it reduce he cost of healthcare in the long run. Biography:Michael Saracen is an independent contractor with over 15 years experience creating, patenting, developing and launching new products and services into the medical device industry. Most recently Michael worked at Accuray Inc. as director of business development focusing on licensing, strategic partnerships, mergers & acquisitions and developing new business opportunities. Prior to his role in business development, Michael was director of product management and product marketing departments overseeing all aspects of the product lifecycle. Before Accuray, Michael worked in three different medical device companies overseeing their Image Guided Surgery product lines. He has extensive experience in robotics, biomaterials, radiation delivery and medical software systems. Michael received his Masters from Brown University in Biomaterials and Artificial Organs. Prior to getting his masters he worked in protein biochemistry research in the Orthopedic Department at Rhode Island Hospital.

While at Accuray Michael was a lead inventor on the RoboCouch, a fully robotic patient positioner, and took the product from concept to prototype in 6 months and received FDA clearance within 9 months. Michael has 7 issued and 12 pending patents covering robotics, quality assurance, tracking & vision systems and treatment planning software. 

See http://ieee.org/scv/embs for further information.

***********************************************************************

5 5/13/2023

BioE2E, Wednesday Evening, May 20, 2009

Topic: “Special challenges in developing and selling HIV/AIDS diagnostics”

Panelists will include Mike Eck, CEO, Acrometrix and Rich Thayer, Halteres AssociatesDate and Time: Wednesday, May 20, 2009,6:45 PM  - 9:00 PMLocation: Wilson Sonsini Goodrich Rosati, 950 Page Mill Rd., Palo Alto, CA 94301Cost: $25 if you register online before noon May 18; $35 at doorRegister at http://www.acteva.com/booking.cfm?bevaID=182853

Topic DescriptionWhen the virus mutates faster than the product cycle, how to entrepreneurs respond?  Join us on May 20, 2009 when we discuss special challenges in developing and selling HIV/AIDS diagnostics.

*************************************************************************

WCC PDA Dinner Meeting, Thursday Evening, May 21, 2009

2009 Professional Dinner Meeting Series

Topic: “Global Regulatory Strategy: Regulatory's Piece of the Puzzle “Speaker: Meredith Brown-Tuttle, RAC, Director, Regulatory Affairs, APT Phamaceuticals, Inc.Date and Time: May 21, 2009 | 6:00 – 9:30 PM Agenda 6:00 PM Registration and Networking Hour 7:00 PM Dinner 7:45 PM Announcements & Chapter Board Elections 8:00 PM Presentation & Discussion 9:30 PM Closing Location: Dominic's at Oyster Point| SSF, CA

Topic Overview

As drug companies seek to penetrate global markets and get new drugs to markets quicker, these companies are increasingly conducting drug and biologic clinical studies outside the United States. The regulatory affairs professional must keep abreast of the ever changing regulatory climate and be able to complete IND like submissions in a variety of formats and country/regulatory agency specific requirements. This presentation will provide an overview of the global regulatory requirements, factors, considerations and timelines for submission and approval of clinical trial dossiers for Canada, EU, South Africa, Australia, Asia and South America.

6 5/13/2023

Registration Submit registration requests via e-mail to rsvp@wccpda.org with "WCC PDA May 21 Dinner RSVP" as the subject line. Indicate name and company affiliation for each registrant and specify if any require a vegetarian meal. It is strongly encouraged that you register in advance to ensure seating at this event, and to allow us to provide the banquent hall with an accurate head count for meals. Pricing Policy

Pre-Registration $ 65.00; Walk-ins/At Door $ 75.00

Payment Options

Cash, check, or credit charge

WCC PDA use PayPal® to process all credit card payments. Access PayPal directly from the chapter website at www.wccpda.org (click the "Events" button and scroll down to the PayPal link). You do not need a PayPal account to use the online payment service and there is no additional fee for registrants. For check payments, you can use the PayPal service or make paper checks payable to "WCC-PDA." If you experience difficulty with the PayPal link, contact the webmaster.

Cancellation Policy

Dinner seating is confirmed and reserved in advance. We regret that no refunds can be offered for non-attendance. If a registrant cannot attend, substitutions are welcome.**********************************************************************Chinese-American Bio/Pharmaceutical Society, 2009 Annual Conference Program, Saturday, May 23, 2009

Topic: Challenges and Opportunities in the U.S. and China: Through the Global Downturn and Beyond Date and Time: May 23, 2009, 8:00 am – 9:00 pmLocation: Crowne Plaza Hotel, 1221 Chess Dr, Foster City, CA 94404, U.S.A. Online Registration at www.cabsweb.org (deadline: May 19)See cost online

8:00am – 9:00am: Registration, networking, wake-up coffee/pastries & vendor show9:00am – 9:10am: Welcome & Opening Remarks (Shichang Miao, Ph.D., President-Elect,

CABS)9:10am – 9:20am: State of the Society (Leping Li, Ph.D., President, CABS)

Plenary Session: Successes, Challenges and Opportunities of the Biotech Industry(co-chairs: Leping Li & Shichang Miao)9:20am – 9:50am: Norbert Bischofberger, Ph.D. (Executive VP R&D and Chief Scientific

Officer, Gilead Sciences): “Gilead Sciences: The Evolution of HIV Treatment and Gilead's Contributions”

7 5/13/2023

9:50am - 10:20am: Nancy Chang, Ph.D. (OrbiMed Venture; Founder of Tanox): Changing nature of Pharma R&D and Outsourcing environment in Asia

10:20am – 10:50am: Karl Sanford, Ph.D. (VP Technology, Genencor): “Recent Developments in Industrial Biotechnology: from industrial enzymes to biochemicals to biofuels”

10:50am – 11:20am: Break, networking & vendor showScientific Session: Advances in Oncology and Neuroscience R&D(co-chairs: Charlene Liao & Wentao Zhang)11:20am – 11:50am: Ira Mellman, Ph.D. (Vice President, Research Oncology, Genentech):

“Oncology Research at Genentech: Where Basic Science Needs No Translation”

11:50pm – 12:20pm: Peter Lamb, Ph.D. (Chief Scientific Officer, Exelixis): “Discovery and Development of Targeted Small Molecule Therapeutics for Oncology”

12:20pm – 1:50pm: Lunch, Networking, Vendor Show1:50pm – 2:20pm Professor Dean Felsher (Stanford University):

“Reversing Cancer through targeted oncogene inactivation”2:20pm – 2:50pm: Alexander “Sasha” Kamb, Ph.D. (Neuroscience Therapeutic Area Head,

Amgen): “Problems and (possible) solutions in the neurosciences therapeutic area”

Session on China Biotechnology and Drug Development2:50pm – 3:20pm: Joseph McCracken, Ph.D. (Vice President, Business Development,

Genentech): "Collaboration: a key to Genentech's success as the leading biotechnology company"

3:20pm – 3:40pm: Break, networking & vendor showTrack 1 Track 2

3:40pm – 4:00pm: Wayne Li, Ph.D. (Morningside Group): “The state and future of biotech funding in China”

Tony Zhang, Ph.D. (Managing Director and site head, China R&D, Eli Lilly):“Pharmaceutical R&D Networks and NME Development Efficiency”

4:00pm – 4:20pm: Jing-shan Hu, Ph.D. (Director Licensing & External Research, Merck): “Maintaining a competitive edge in a changing landscape”

Yingfei Wei, Ph.D. (Chief Scientific Officer, 3SBio): “Biosimilars in China: current state and future”

4:20pm – 4:40pm: Jintao Zhang, Ph.D. (CEO, Shanghai Medicilon): “The CRO business in China today and tomorrow”

Allan Riting Liu, Ph.D. (Shanghai Fosun Pharmaceutical Group): “Fosun Pharma and its licensing and R&D alliance strategy”

4:40pm – 5:00pm: Ningni Yu, Ph.D.: (GM, Zhangjiang Pharm. Engine Co.Ltd): “Zhangjiang,One of the Most Innovative Life Science Cluster in China”Presentation by Gold Sponsor: Pharmaron

Presentation by Gold Sponsor: AzoPharma

5:00pm – 5:10pm: Presentation by Gold Sponsor:GenScript

8 5/13/2023

5:10pm – 5:40pm: Break, networking & vendor show

5:40pm – 6:00pm: Platinum Sponsor's presentation: Taicang Science Park6:00pm – 6:15pm: Solo Performance: Soprano Ms. Manhua Gao (著名女高音歌唱家高曼华)6:15pm – 7:15pm: Banquet & Entertainment

Expert Forum & Panel Discussion 7:15pm – 9:00pm: Topics:

Bio/Pharma trends Entrepreneurship Managing through Mergers & Acquisitions Career transition and development in a challenging time

Mini Keynote: Brian Cunningham, J.D. (Senior Counsel and Co-Chair of the Life Science Group, Morrison & Foerster): title TBD

Distinguished Panelists / discussion focuses: Jin-Long Chen, Ph.D. (Founder & President, NGM

Biopharmaceuticals): drug discovery entrepreneurship; managing through merger & acquisitions

Cheni Kwok, Ph.D. (Senior Vice President, Corporate Development, Poniard Pharmaceuticals): “Dress for Success - Managing the Partnership Process”

Jay Tong, Ph.D. (Founder & Chief Executive Officer, Allcells): Entrepreneurship and service-based business

Larry Wang, Ph.D. (Co-Founder & President, GenScript): “Boost the Innovation Capacity by Integrating with a China Biology CRO”

Alex Wu, Ph.D. (Co-founder & Chief Executive Officer, Crown BioScience): U.S.-China entrepreneurship

Zhenyu Yuan, Ph.D. (Founder & Chief Executive Officer, MicuRx): U.S.-China-based drug discovery

***************************************************************************Bio2Device Group, Tuesday Morning, May 26, 2009

Topic: “Cultivating Personal Leadership in Changing Workplace and Marketplace”Speaker: Darshana V. Nadkarni, Ph.D, Principal, Winning DifferenceDate and Time: Tuesday, May 26, 2009, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: FreeParking on street and in NOVA and library parking lots across the street.

Topic Description

9 5/13/2023

This will be an interactive dialogue, with possibly some small group activity.  We will discuss the changes impacting the workplace and marketplace.  We will explore how we can take an empowered stance and assume leadership amidst the changes and challenges so that we can continue to grow in our personal and professional journey, that is in alignment with our vision and goals. Speaker Bio Darshana Nadkarni completed her PhD in Psychology from University of Cincinnati.  Currently, she provides recruiting services to medical device and biotech startups. Darshana also has over 15 years of experience as trainer, educator, facilitator, and writer.  She facilitated trainings in leadership, diversity, and workplace inclusion to such organizations like IBM, Verizon Wireless, Mastercard, CocaCola, Dow Corning to name a few.  She has taught classes at St. Mary's College, Santa Clara University, and Cal State, Hayward.  She often writes articles for local Indian news magazines.**************************************************************************

Silicon Valley Chapter LES, Wednesday Lunchtime, May 27, 2009

Topic:  “The Changing Patent Landscapes in India and China”Speaker: George Sawyer, Evalueserve

Date and Time: Wednesday, May 27, 2009 Meeting format:11:30 – 12:30              Registration and Networking buffet lunch12:30 – 2:00                Program

Location:Hosted by Townsend and Townsend and Crew LLP, 390 Lytton Avenue, Palo Alto, CA  94301, (650) 326-2400

Topic DescriptionChina and India are the two of the fastest growing markets in the world. China is rapidly becoming the "manufacturing hub" for the developed world whereas India is the "services hub."  This presentation is a look at the patent systems, patenting, and litigation in both of these countries, and summarizes Evalueserve white papers on the two countries.  Evalueserve research shows that China is today the third largest patent jurisdiction (by annual filing volume), more patents are filed in China than in the EPO, and that China is now the most litigious IP venue in the world, with multi-million dollar verdicts.  We'll present data on trends, regulations, and some best practices for these two countries.

Click here for detailed -- http://www.lesusacanada.org/MainNav/LocalChapters/LES-USA-West/Silicon-Valley/May-28.aspx

Speaker Bio

George is an engagement manager for Evalueserve.  After studying computer science at MIT, he spent 15 years in the software industry including three years in Tokyo as Director of

10 5/13/2023

Product Development for Computervision Japan Ltd.  In 1995 he made the switch to intellectual property, joining the Boston firm Global Prior Art as director of business development and senior analyst.  In 2004 he joined Evalueserve to help build Evalueserve's IP practice, focusing on patent landscaping and portfolio analysis.  When he is not working, he is brewing beer that ages like wine and bicycling to burn off the calories from the beer.

LES Member Registration Fee:$45 by Friday, May 22 (2pm pst)$50 after Friday, May 22Non-Member Registration Fee: $50 by Friday, May 22 (2pm pst)$55 after Friday, May 22

*Members of the following organizations will receive the LES Member rate:ALM, Bay Bio, The Churchill Club, International Business Forum, LARTA, Ocean Tomo, Practicing Law Institute, San Jose Bio, Tech Connect

*To receive the LES Member rate, click on the PARTNER link

For questions about online registration:

Curtis GoreLES Chapters CoordinatorLES USA & CanadaAlexandria, VA  22314cgore@les.org(703) 836-3107

Pay by checkMail check and completed registration form to: Licensing Executives Society USA and Canada Inc.1800 Diagonal Road, Suite 280 Alexandria, VA  22314

For questions about the meeting:

Franca GargiuloLES Silicon Valley Chapter Coordinator franca.gargiulo@att.net(415) 564-2600

11 5/13/2023

*************************************************************

French American Chamber of Commerce (FACCSF) Life Sciences Committee, Wednesday Evening, May 27, 2009 

Topic: Alliance Management: Maximizing your chances for success. Perspectives from big, small and global life sciences companiesPanel of experts Jeet Mahal - Head of Alliance Management, Portola Pharmaceuticals

Alliance management in West Coast biotech firms: Challenges of initializing and maintaining a working partnership across differences in size, geography, language and culture.

Christophe Degois – Biotech Executive specializing in Marketing – Business Development – Global Operations

Managing alliances in different countries with different partners for the same compound. How to support your partners to maximize sales outside the U.S. How to influence your partners to pay attention to your product and evaluate their performance.

Xavier Avat - Director Global Alliance Management, Gilead

Lessons learned from starting a new Alliance Management department. What structure works best to keep relationships and business running smoothly for the common good.

Moderator: Norma Watenbaugh - Founding Principal Phoenix Consulting Group Date and Time: Wednesday, May 27th, 6.30 pm - 9.00 pm at GileadLocation: Gilead, 333 Lakeside Drive, Foster City, CA 94404 - Directions Cost: $20 for member and $25 for nonmembers

Registration at http://www.faccsf.com/Events/LSB_May09.htmTopic Description Strategic alliances are becoming vital for biotech companies, as a key to share risks and rewards. Learn from small, big, and global life sciences companies on how to build a symbiotic and healthy alliance. *************************************************************

Palo Alto AWIS, Wednesday Evening, May 27, 2009\

Topic: “From Worms to Humans: Genes that Control the Rate of Aging”Speaker: Dr. Cynthia Kenyon http://kenyonlab.ucsf.edu/ Date and Time: Wednesday, May 27th, 2009

12 5/13/2023

Schedule7:00-7:30 pm Networking and light supper7:30-7:45 pm Announcements7:45-8:45 pm Program8:45-9:00 pm Discussion

Location: PARC Auditorium, 3333 Coyote Hill Road, Palo AltoRSVP: online http://www.acteva.com/go/pa-awisWelcome!! You donʼt need to be a member to attend.All scientists, students, and their friends are welcome. Men too!Members pay $4 and non-members pay $7 to offset the cost of food.

Topic DescriptionAging was once thought to be a completely haphazard process; we wear out, like oldshoes. Now we know that there are actually genes that control the rate of aging.These genes were first discovered in the small roundworm C. elegans, but the samegenes are now known to affect lifespan in higher animals, even humans. Changingthese genes in roundworms can double the lifespan of the animal, and makingseveral changes at once can extend lifespan by six-fold. In this lecture, Dr. Kenyonwill discuss the nature of these genes, explain how we think they can influence therate of aging, and discuss prospects for using this information to increase our ownhealth and longevity.

Speaker BioCynthia Kenyon received her PhD from MIT in 1981, and then studied with Nobellaureate Sydney Brenner in Cambridge, England. Since 1986, she has been at theUniversity of California, San Francisco, where she is now an American CancerSociety Professor. In 1993, Dr. Kenyon's discovery that a single mutation coulddouble the lifespan of C. elegans sparked an intensive study of the molecular biologyof aging. Dr. Kenyon has received many awards for her findings. She is a memberof the US National Academy of Sciences, the American Academy of Arts andSciences, and the Institute of Medicine and she is a past-president of of the Genetics Society of America.***************************************************************************BioDesign Program Innovator’s Workbench Series, Wednesday Evening, May 27, 2009

Speaker: David Dvorak President & CEO, Zimmer, Inc.Date and Time: Wednesday, May 27, 20095:30 - 6:30 pmLocation: Bishop Auditorium - Graduate School of Business - 518 Memorial Way Stanford, CA 94305

Topic DescriptionThe Stanford Biodesign Program, Windhover Information, Wilson Sonsini Goodrich & Rosati and PricewaterhouseCoopers present a unique opportunity to hear our third and final innovator for the 2009 “From the Innovators Workbench” Series.  David Dvorak, President

13 5/13/2023

and CEO of Zimmer, Inc., will be interviewed by David Cassak, Managing Partner, Windhover Information.Directions to the Graduate School of Business and map:http://www.gsb.stanford.edu/mba/contact/directions.htmlFor more information about David Dvorak please follow the following link.http://biodesign.stanford.edu/bdn/people/dvorak_david.jsp Register at:  http://www.register123.com/event/profile/form/index.cfm?PKformID=0x708302d0acFor further information please contact:Mary Gorman, Biodesign Program, (650) 736 1161, marygorman@stanford.edu or  http://biodesign.stanford.edu/*************************************************************************Bay Bio Therapeutic Breakfast, Thursday Morning, May 28, 2009

Topic: “Regulatory Environment for Pain Therapeutics”Panel Moderator: Stephen Thau, Partner, Morrison & Foerster LLPPanel Speakers: Michael Leong, MDPain Medicine Specialist, Adjunct Assistant Professor, Stanford University Pain Management CenterGayle Mills, EVP, Business Operations, ROXRO Pharma, Inc.Pamela Palmer, Chief Medical Officer, AcelRx Pharmaceuticals, Inc.Date and Time: May 28, 8:00am - 10:00amLocation: KPMG, 500 E. Middlefield Road, Mountain View, CA

Topic DescriptionPain treatment is big business, with several multi-billion dollar per year pain therapeutics on the market, and several others with sales of more than $100 million per year. Misuse and abuse of pain drugs is also a big problem. According to the FDA, the misuse and abuse of pain therapies has increased significantly in the past five years. Looking to reverse this trend, the FDA is requiring manufacturers of opioid products to implement Risk Evaluation and Mitigation (REMS) strategies, which the agency is in the process of developing. Come hear our panel of experts discuss how the new REMS guidelines will change the landscape of pain therapies.

Registrations:If you are an employee of a Partner or Sponsor company, please contact Program Director, Misha Tsirulnikov to obtain your complimentary registration.

On-line reservations: CLICK HEREReservations by mail or fax: CLICK HEREEarly Bird Registration through May 26, 2009:$10.00 BayBio Members$20.00 Non-Members

14 5/13/2023

On-Site Registration, May 28, 2009:$20.00 BayBio Members$40.00 Non-Members

Pre-registered attendees will receive an immediate receipt/confirmation after submission. Please print this receipt/confirmation and bring it with you to receive your conference credentials. Photo ID (driver's license or passport) will be required at check-in.

All sales are final - BayBio offers no refunds.

Please mail your event-related questions to: events@baybio.org or you can contact us via phone: 650-871-7101. ******************************************************************

East Bay AWIS, Thursday Evening, May 28, 2009

Topic: "Career Focus: From Science to Sales” Speakers: Panel of scientists who used their science background in sales careersDate and Time: Thursday, May  28th, 2009            6:30 PM Light dinner*            7:00 PM -8:30 PM Panel              Location: Novartis**,             New Location--Building X-310, 5300 Hollis St, Emeryville, CA            **This location might change depending on Novartis Health Policies in                 response to the H1N1 Virus WHO Threat Level .  Please check back for                     updates. COST: * A contribution of $5 (members) to $10 (non-members) to cover cost of food is encouraged. RSVP here. Enter 1 for "Quantity" on RSVP site and pay donation in person.FlyerMap

Panelists:  Goli Fahid has 8 years of experience in Bio tools sales & marketing and currently holds a technical sales position with LICOR Biosciences. LI-COR Biosciences is a leader in the design and manufacture of instrument systems for biotechnology and environmental research. She is based in East Bay and her territory includes Northern California, Washington and Oregon.  Her work has included, but is not limited to calling on researchers and increasing LICOR’s market share through seminars, workshops and demonstrations. Goli has a B.S. in Genetics and a minor in Computer Science from UC Davis.

 Kevin Lindquist received his M.S. in Chemical Engineering from the State University of New York at Buffalo where he studied fluid mechanics and protein surface binding in biosensor devices.  Following his graduate studies, he worked as a research scientist and project leader at Alnis Biosciences, Inc. where he

15 5/13/2023

synthesized and characterized novel nanoparticles for potential use in targeted drug delivery applications. Following his work at Alnis BioSciences, Kevin joined Biacore, Inc (Part of GE Healthcare) where he has been working for the past 8 years. Currently, he is a Principal Application Scientist in the San Francisco Bay Area where he works with biosensor users in the field, instructs biosensor users at a variety of Biacore training courses, and performs proof-of-concept biosensor studies.

 Michelle Alegria-Hartman recently transitioned from a research position, as a Biomedical Scientist at Lawrence Livermore National Laboratory, to VWR as a Life Science Specialist in the sales/marketing group.  She has worked on numerous projects including several biodefense projects and the Human Genome Project.  Her research has spanned areas of molecular biology, microbiology, genomics, and proteomics.  Michelle received her Ph.D. in Molecular Genetics from the University of California, Davis in 2002.

 Sharon Squazzo is a Biotechnology Specialist with Sigma Aldrich.  This is a technical sales position representing the life science technologies of Sigma Aldrich at academic, biotech and pharmaceutical institutions in the Bay Area  Prior to joining Sigma Aldrich  in 2007, Sharon worked for fifteen years in molecular and cellular biology research at Harvard Medical School, Millennium Pharmaceuticals, UC Santa Cruz and the UC Davis Genome Center.  Sharon has a B.S. in Microbiology from University of Massachusetts, Amherst.

Special thanks to Aerotek Scientific for sponsoring this May meeting. NON-SCIENTISTS, MEN ARE ALL WELCOME!**This location might change depending on Novartis Health Policies in response to the H1N1 WHO Threat Level .

*************************************************************************Bay Bio Hot Topics Series, Thursday Afternoon, May 28, 2009

Topic: “Challenges, Opportunities and Perspectives for Biofuels,”,Date and Time: Thursday Afternoon, May 28, 29009

2:30 - 3:00pm: Registration3:00 - 3:20pm: What Does the Future Hold for Innovation3:30 - 4:30pm: Challenges and Opportunities4:30 - 5:30pm: Energy Policy and Economic Stimulus5:30 - 6:30pm: Reception and Networking

Location: Applied BioSystems, 600 Lincoln Centre Drive, Building 600, Foster City, CA; Ample parking available at no cost in the employee lot.

Registrations:

If you are an employee of a Partner or Sponsor company, please email events@baybio.org to obtain your complimentary registration.

16 5/13/2023

On-line reservations: http://www.acteva.com/booking.cfm?bevaid=183261Reservations by mail or fax: CLICK HERENo on-site registration will be provided to this event.Registration through May 26, 2009:$20.00 BayBio Members$40.00 Non-Members

Pre-registered attendees will receive an immediate receipt/confirmation after submission. Please print this receipt/confirmation and bring it with you to receive your conference credentials. Photo ID (driver's license or passport) will be required at check-in.

All sales are final - BayBio offers no refunds. Please mail your event-related questions to:events@baybio.org or you can contact us via phone: 650-871-7101.

Topic DescriptionReplacing oil with next generation biofuels as the foundation of the world's transportation system spurs the imagination of innovators, researchers, entrepreneurs and investors. Bringing biofuel innovations to market is challenging, however, due to both scientific and monetary concerns. Two panels will address these issues; the first panel will focus on the science and commercialization challenges and opportunities in the biofuels market, the second panel will focus on current energy policies of the US government, its approach to supporting next generation biofuels, and the impact of the economic stimulus package on the biofuels industry. Join us for this exciting event!

***********************************************************************Bio2Device Group, Tuesday Morning, June 2, 2009

Topic: TBASpeaker: Gabriela Zelaya, International Trade Specialist,U.S. Commercial ServiceDate and Time: Tuesday, June 2, 2009, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: Free

17 5/13/2023

Parking on street and in NOVA and library parking lots across the streetSee details at www.Bio2DeviceGroup.org

****************************************************************National Instruments Free Seminar, All Day, June 4, 2009

Topic: Medical Device Development From Concept to ApprovalDate and Time: June 4, 2009 8:45 a.m. - 4:30 p.m.Location: Location: Crowne Plaza Foster City, 1221 Chess Drive, Foster City, CA 94404To register, e-mail register@ni.com or call (888) 444-3539

National Instruments invites you to a full-day event on graphical system design and how it can help you develop high-quality medical devices in half the time of traditional methods. This complimentary seminar featuring presentations, hardware and software demonstrations, and case studies takes attendees through the creation of a medical device from concept to market.

Fostering Innovation in Medical DevicesIt is estimated that the U.S. medical device market is a $57.6 billion industry and, with an increased demand for medical therapies and treatments, a new generation of medical device companies is emerging. According to the U.S. Food and Drug Administration, one of the most important aspects of getting a medical device product to market is knowing where to begin and how to ensure compliancethroughout the development life cycle.

In this seminar:• Learn how to design, prototype, and deploy FDA-compliant medical devices• Discover how NI LabVIEW is used by scientists to complete their research on time and by engineers to shorten development timelines• Hear industry experts discuss their approaches to the medical device life cycle• Explore technology innovations in software and hardware, including commercial off-the-shelf (COTS) hardware used to design medical devices• Examine case studies by system and application integrators who havesuccessfully deployed medical devices

Who Should Attend:This event is designed for biomedical or life science engineers, scientists and technicians who design, build or test Class I, II or III medical devices.

Host:Northern California Sales Team*****************************************************************Bay Bio Medical Device Breakfast, Tuesday Morning, June 9, 2009

Topic: Enterprise Risk Management through IP ProtectionDate and Time: Tuesday, June 9, 2009, 8:00 – 10:00 am

18 5/13/2023

Location: Cooley Godward Kronish LLP, Palo Alto, CAPanel Moderator: Thomas Meyers, Partner, Cooley Godward Kronish LLP

Panel Speakers:Earl "Eb" Bright, General Counsel and Vice President, Intellectual Property, Exploramed Development, LLC

Kimberly Cauthorn, Director - North America, SAMIAN Underwriting

Steven Gerbsman, Principal, Gerbsman Partners

Tony WondkaVice President of Technology, Breathe Technologies, Inc.Registrations:If you are an employee of a Partner or Sponsor company, please contact Program Director, Misha Tsirulnikov to obtain your complimentary registration.

On-line reservations http://www.acteva.com/booking.cfm?bevaid=182585Reservations by mail or fax: CLICK HERE

Early Bird Registration through June 7, 2009:$10.00 BayBio and MDMA Members, Bio2Device and Bio-X Affiliates$20.00 Non-Members

On-Site Registration, June 9, 2009:$20.00 BayBio and MDMA Members$40.00 Non-Members

Pre-registered attendees will receive an immediate receipt/confirmation after submission. Please print this receipt/confirmation and bring it with you to receive your conference credentials. Photo ID (driver's license or passport) will be required at check-in.

All sales are final - BayBio offers no refunds.

Please mail your event-related questions to: events@baybio.org or you can contact us via phone: 650-871-7101.

Topic DescriptionAs innovators and leaders in a dynamic and competitive industry, Medical Device Companies of all stages of development share one thing in common. Intellectual Property. Protecting IP is a global issue that acutely affects the Medical Device industry. Whether you are an early stage start up, in clinical trials or have reached commercialization, your IP is your biggest asset. Join our panel for a discussion on how to protect, manage and defend you’re your Intellectual Property. Among the topics that will be addressed, strategy to

19 5/13/2023

prevent, or prevail in: enforcement; invalidity / title or ownership; infringement liability and defense; loss of value or revenue; contractual obligations.*************************************************************************

Bio2Device Group, Tuesday Evening, June 9, 2009

Topic: “MS Health Technology Assessment”Speaker: John Hornberger, MD, Date and Time: Tuesday Evening, June 9, 2009, 6:00 – 9:00 pmEvent Schedule:6:00 to 6:45 pm --Join us for a light dinner and networking6:45 pm to 8:15 --Meeting will begin with B2DG Business, followed immediately by John Hornberger’s presentation, Discussion, & followed by open networking9:00 pm - Close of networkingLocation: TIPS, 1000 Elwell Court, Palo Alto, CASmall charge for light mealSee details for registration at www.Bio2DeviceGroup.org

********************************************************************

BioE2E, Wednesday Evening, June 10th

Topic: “Alternative Financing for Alternative Energy” Location: UCSF Mission Bay. Byers Auditorium Date and Time: Wednesday, June 10, 2009, 2pm-5pm followed by a reception Co-Sponsored by QB3 (www.qb3.org)--Find out what  government agencies are investing in green and clean tech--Learn from fellow entrepreneurs about how to get funding--Explore applications of biology and chemistry in the alternative energy arena

--Meet with VCs active in this space--Network with fellow entrepreneurs and collaborators--Identify pathways to commercialization ***************************************************************************************** 

San Jose BioCenter, Thursday Afternoon, June 11, 2009

Topic: Making Yourself a Target

Confirmed Speakers:Mark Edwards, Principal, Deloitte Recap LLCPeter Condon, Associate Director, GenentechSara Hall, CEO, Tacere Therapeutics

20 5/13/2023

Lee Bendekgey, former CFO and General Counsel, NuveloJim Schaeffer, Executive Director, Licensing And External Research, Merck Research Laboratories, Merck & Co., Inc.Lead Facilitator: Gregory Heibel, Partner, Orrick Date and Time: Thursday, June 11, 2009 | 3pm-6:30pm Location: Orrick, Herrington & Sutcliffe LLP, 1000 Marsh Road, Building 1100, Menlo Park, CA 94025-1015Click here for Venue Directions»

This event is typically sold out, therefore please register early to secure your spot.• Panel and Networking Reception:   ° Partners Network: $40   ° Pre-registration: $45   ° Onsite Registration: $55

Register at http://www.acteva.com/booking.cfm?bevaID=177014

Event DescriptionMergers and Acquisitions are on the rise, and businesses throughout the industry are preparing their next steps.  Big BioTech companies have the power to purchasing 2009 intellect for 1999 prices.  Find out what it takes to make your business attractive to larger companies, while maintaining worth.  Discover who’s looking, and how to become a M&A target.  Join this panel to hear M&A strategy perspectives from the purchased, the purchaser, the investor, and the lawyer.  This panel will give you the opportunity to meet with M&A pros, and help you plan your next move. 

Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.

Click here for more information ************************************************************************BioE2E, June 16-17, 2009

Topic: “Alternative Financing for Regenerative Medicine Companies”Confirmed speakers as of May 9, 2009 are Dr. Michael Clarke, Oncomed; Dr. Chris Airriess, California Stem Cells, Inc; Jeff Karan, Proteus Venture Partners; Dr. Jon Mogford, DARPA; Dr. Eva Lai, USAMRMC; Dr. Holly Campbell-Rosen, CDMRP; Paul Pickering, Invitrogen; tbn, Fast Forward; Dayton Coles, JDRF; and Dr. Sophia Colamarino, Autism Speaks. Date: June 16 & 17 Location: SRI International, Menlo Park.  Event Description The first day is a poster-and-networking session.  The second day we have invited speakers from military medical research, biomedical foundations, corporate venture capital and federal

21 5/13/2023

programs like NIH and NCI.   Speakers from leading regenerative medicine companies Oncomed and California Stem Cells, Inc. kick off our panel sessions on the second day.   We see regenerative medicine as therapies cell-based, biologics and small molecules as well as diagnostics, biomarkers and methods that can restore function, or help us understand how to treat damaged tissue, degenerative conditions or genetic disease.  If you are in the field of regenerative medicine, whether you are an academic scientist contemplating commercialization of an idea or an emerging company looking for non-venture sources of funding, please join us.

For more information go to www.bioe2e.org

Register online for any of our events at  www.acteva.com/go/bioe2e

************************************************************************Recap’s Allicense Meeting, Wednesday and Thursday, June 17-18, 2009

Topic:” Bridging the Gap from Biomedical Research to Commercialization” Event: Allicense 2009--13th Annual Biotechnology Business Development and Licensing ConferenceDate and Time: Wednesday and Thursday, June 17-18, 2009Location: The Fairmont San Francisco, 950 Mason Street, San Francisco, CA  94108Phone: 415-772-5000, Fax: 415-772-5013Cost: Allicense 2009 Registration - US $1850.00

Registration fee includes 2 days of conference sessions, continental breakfasts and seated luncheons on both days, and attendance to the Breakthrough Alliance Awards Ceremony and Dinner on June 17, 2009.

DescriptionAllicense is biotechnology’s top business development and licensing conference forexecutives, For more than a decade they’ve built panels around in-depthanalysis and a passion for licensing. They place their panel speakers in lively and candid conversations with the audience.  There is no better place to learn what’s really going on in biotechbusiness development.RegistrationYou can register for the conference online at:

http://www.recap.com/allicense

Speakers include:

Corey Goodman, PhDPresident, Biotherapeutics &

Bioinnovation CenterPfizer

22 5/13/2023

James C. GreenwoodPresidentBiotechnology Industry Organization

Mikael Dolsten, PhDPresidentWyeth Research

Jeffrey M. Bockman, PhDVice PresidentDefined Health

Graham R. BrazierVP, Strategic Transactions GroupBristol-Myers Squibb

Frances K. HellerEVP, Business DevelopmentExelixis

Thomas Hofstaetter, PhDSVP, Corporate Business DevelopmentWyeth

Richard M. Keenan, PhDVP, Business OpportunitesCEEDD, GlaxoSmithKline

Dr. Donald R. JohnsHead of Translational MedicineNovartis AG

Barbara KosaczHead, Life Sciences PracticeCooley Godward Kronish

Joseph S. McCrackenVP, Business & Commercial DevelopmentGenentech

Mark Noguchi

Global Head of Alliance Management & OperationsRoche Pharma Partnering

Stuart W. Peltz, PhDPresident & CEOPTC Therapeutics

Angus RussellChief Executive OfficerShire plc

Adriann SaxEVP, Business Development & Strategic PlanningKing Pharmaceuticals

George A. Scangos, PhDPresident & CEOExelixis

Chen SchorVP, Business Development, Global Branded ProductsTeva Pharmaceuticals

R. Christopher SeatonSVP, Global TransactionsBayer Healthcare Pharmaceuticals

John R. TupmanSr. Director, Corporate Business DevelopmentEli Lilly & Co.

Klaus K. Wilgenbus, MDCorporate SVP, Head of Global LicensingBoehringer Ingelheim

Barbara YanniVP & Chief Licensing OfficerMerck & Co.

**************************************************************************Intensive Bioscience Business Development Course, All Day, June 25-26, 2009

Event: Intensive 2-day course in Business Development and Licensing

23 5/13/2023

Instructors: Audrey Erbes, Ph.D. and Gil Mintz, Instructors Expert Guest Lecturers:Harold (Hal) Etterman, MBA, Business StrategistCarolyn Feamster, MBA, VP, Business Strategy & Analysis Tom Gutshall, Chairman & Co-Founder of CepheidMichael G. McCully, M.S., Director, Recombinant Capital Herwig von Morze, Ph.D., International Patent Consultant

Date and Time: Thursday and Friday, June 25-26, 2009, 8:30 am – 5 pmLocation: 10420 Bubb Road, CupertinoCost: $770 (Discounted price- $693 through June 11)

Topic DescriptionUCSC Extension in Silicon Valley presents a two-day intensive course that brings the breadth of the Bay Area’s biobusiness development expertise to our Cupertino classroom. Whether financing start-up activities, trying to keep pace with the current burn rate, or moving a product into the marketplace, bioscience companies, both large and small, have a critical need for business development at every stage of their evolution. Learn the key roles that business development and licensing play in the commercialization of a new product and the development of a successful bioscience company. Cupertino, CA. For more information, see www.ucsc-extension.edu/biosciences.

*************************************************************************

24 5/13/2023